VBI's shares plunge after hep B vaccine fails secondary goal in late-stage trial
VBI Vaccines Inc said on Monday a late-stage study was unsuccessful in showing two doses of its hepatitis B vaccine were as effective as three doses of an older vaccine from GlaxoSmithKline, sending its shares plunging 66%.
ConclusionsOur prospective study performed in a real-world setting showed a high immunogenicity and safety of HBV-AS04 vaccine in patients with CKD not yet on maintenance dialysis. Studies provided with longer follow-ups are under way to assess the durability of seroprotection in responders.
There is limited data regarding the use of emergency departments (EDs) for infectious disease screening and vaccination in resource-limited regions. In these settings, EDs are often the only contact that patients have with the healthcare system, turning an ED visit into an opportune time to deliver preventative health services.
This review examined the current evidence for the efficacy and safety of therapeutic vaccines compared to no treatment, placebo or standard care in the treatment of chronic hepatitis B.Journal of Viral Hepatitis
Abstract OBJECTIVE: To assess vaccination coverage and predictors of vaccination among a Canadian population of rheumatology patients in routine clinical care. METHODS: In this cross-sectional study, consecutive adult patients presenting to a tertiary rheumatology clinic at the McGill University Health Center between May and September 2015 were asked to fill a survey on vaccination. Patients self-identified as having rheumatoid arthritis (RA), systemic autoimmune rheumatic diseases (SARD), spondyloarthropathies (SpA), or other diseases (OD). Multivariate logistical regression analyses were performed to evalua...
More than 240 million people worldwide are chronically infected with the hepatitis B virus (HBV) [1 –2]. In the Asia-Pacific region, where it is most prevalent, chronic HBV infection is the leading cause of cirrhosis, liver failure, and hepatocellular carcinoma [2–6]. While currently approved oral nucleos(t)ide analogs effectively suppress viral replication, providing important clinical benefi ts, there are several disadvantages of this therapeutic approach. First, since antiviral therapy is rarely curative, most patients must receive life-long treatment with the attendant cost, cumulative toxicity, and risk of...
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response. The material can give rise to a polyvaccine against six diseases.
CONCLUSIONS: Dose-series completion was low in all settings, but lowest where patients may be less likely to return for follow-up (e.g., STD clinics). Routinely assessing HepB vaccination needs of high-risk adults, including through use of IIS where available, may facilitate HepB vaccine dose-series completion. PMID: 31303523 [PubMed - as supplied by publisher]
Jul 30, 2019. . Sponsored by Association of Asian Pacific Community Health Organizations
ConclusionsThis study found that the LTFU rate reached 20% in PVST program, which was a significant problem. We recommend implementing a national electronic information system for tracking HBV at risk mother-infant pairs; encourage further research in developing a less invasive means of completing PVST, and take effective measures nationally to reduce HBV stigma. Without reducing the loss to follow up rate among infants eligible for PVST, elimination of vertical HBV transmission will be impossible.
Circulating interferon-λ3 and post-vaccination antibodies against the surface antigen of hepatitis B virus in hemodialysis patients exposed to hepatitis E virus. Cytokine. 2019 Jul 03;123:154766 Authors: Grzegorzewska AE, Świderska MK, Winnicka H, Niepolski L, Bura M, Łagiedo-Żelazowska M, Jagodziński PP Abstract Responsiveness to the hepatitis B virus (HBV) vaccination in hemodialysis (HD) patients who had been exposed to the hepatitis E virus (HEV) and persistently generate antibodies against HEV remains unknown. Interferon (IFN)-λ3 positively correlates with the surface HBV antibo...